Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pendleton

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
JAMA|September 4, 2019
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical TrialBrian F Gage, Anne R Bass, Hannah Lin, et al.
Clinical Pharmacology and Therapeutics|April 9, 2010
Integration of genetic, clinical, and INR data to refine warfarin dosingP Lenzini, M Wadelius, S Kimmel, et al.
Thrombosis and Haemostasis|December 22, 2011
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyBenjamin D Horne, Petra A Lenzini, Mia Wadelius, et al.
The New England Journal of Medicine|November 21, 2013
A pharmacogenetic versus a clinical algorithm for warfarin dosingStephen E Kimmel, Benjamin French, Scott E Kasner, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
JAMA|September 4, 2019
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical TrialBrian F Gage, Anne R Bass, Hannah Lin, et al.
Clinical Pharmacology and Therapeutics|April 9, 2010
Integration of genetic, clinical, and INR data to refine warfarin dosingP Lenzini, M Wadelius, S Kimmel, et al.
Thrombosis and Haemostasis|December 22, 2011
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyBenjamin D Horne, Petra A Lenzini, Mia Wadelius, et al.
The New England Journal of Medicine|November 21, 2013
A pharmacogenetic versus a clinical algorithm for warfarin dosingStephen E Kimmel, Benjamin French, Scott E Kasner, et al.
Pageof 9